Johnson & Johnson (JNJ) Operating Cash Flow CAGR:N/A(TTM)
The operating cash flow cagr for Johnson & Johnson (JNJ) is N/A over the latest trailing 12-month period. Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
The operating cash flow cagr for Johnson & Johnson (JNJ) stock is N/A over the past 12 months. The 3 year average growth rate is 2.38% and the 5 year cagr is -0.55%. Operating cash flow CAGR measures the compound annual growth rate of the cash Johnson & Johnson generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history. The 1-year (TTM) figure is omitted: a one-year rate off a single quarter's base is volatile; the multi-year figures are the reliable read.
JNJ Operating Cash Flow CAGR Chart
Johnson & Johnson (JNJ)
JNJ Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $24.27B | $24.53B | +$264.00M | +1.09% | +1.09% |
| 2024 | $22.79B | $24.27B | +$1.48B | +6.47% | +6.47% |
| 2023 | $23.41B | $22.79B | $-619.00M | -2.64% | -2.64% |
| 2022 | $23.54B | $23.41B | $-126.00M | -0.54% | -0.54% |
| 2021 | $23.42B | $23.54B | +$120.00M | +0.51% | +0.51% |
| 2019 | $22.20B | $23.42B | +$1.22B | +5.47% | +5.47% |
| 2018 | $21.06B | $22.20B | +$1.15B | +5.44% | +5.44% |
| 2017 | $18.77B | $21.06B | +$2.29B | +12.20% | +12.20% |
| 2016 | $19.28B | $18.77B | $-512.00M | -2.66% | -2.66% |
| 2015 | $18.47B | $19.28B | +$808.00M | +4.37% | +4.37% |
| 2014 | $17.41B | $18.47B | +$1.06B | +6.07% | +6.07% |
| 2013 | $15.40B | $17.41B | +$2.02B | +13.11% | +13.11% |
| 2012 | $14.30B | $15.40B | +$1.10B | +7.68% | +7.68% |
| 2011 | $16.39B | $14.30B | $-2.09B | -12.74% | -12.74% |
| 2010 | $16.57B | $16.39B | $-186.00M | -1.12% | -1.12% |
| 2009 | $14.97B | $16.57B | +$1.60B | +10.68% | +10.68% |
| 2008 | $15.25B | $14.97B | $-277.00M | -1.82% | -1.82% |
| 2007 | $14.25B | $15.25B | +$1.00B | +7.03% | +7.03% |
| 2006 | $11.88B | $14.25B | +$2.37B | +19.96% | +19.96% |
| 2005 | $11.13B | $11.88B | +$746.00M | +6.70% | +6.70% |
| 2004 | $10.60B | $11.13B | +$536.00M | +5.06% | +5.06% |
| 2003 | $8.18B | $10.60B | +$2.42B | +29.59% | +29.59% |
| 2002 | $8.86B | $8.18B | $-688.00M | -7.76% | -7.76% |
| 2001 | $6.56B | $8.86B | +$2.30B | +35.06% | +35.06% |
| 2000 | $5.68B | $6.56B | +$886.00M | +15.61% | +15.61% |
| 1999 | $4.89B | $5.68B | +$791.00M | +16.19% | +16.19% |
| 1998 | $4.34B | $4.89B | +$543.00M | +12.50% | +12.50% |
| 1997 | $3.89B | $4.34B | +$452.00M | +11.62% | +11.62% |
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato